Imaging Biometrics, LLC a wholly owned subsidiary of IQ-AI Ltd. announced it has submitted a Pediatric Rare Disease ("PRD") request to the US Food and Drug Administration ("FDA") for oral gallium maltolate ("GaM") for the treatment of pediatric brain tumors. The RPD program is intended to encourage the development of new drugs for the treatment of rare pediatric diseases and is granted by the FDA for serious or life-threatening diseases which affect fewer than 200,000 people under the age of 18 years in the U.S. If IB's application is successful, the PRD designation provides incentives including eligibility for a priority review voucher that can be redeemed for a subsequent marketing application. This voucher can be used to reduce the time of an FDA new drug approval review or could be transferred (sold) to another company.